Literature DB >> 18193162

Thrombospondins in cancer.

S Kazerounian1, K O Yee, J Lawler.   

Abstract

The thrombospondins (TSPs) are a family of five proteins that are involved in the tissue remodeling that is associated with embryonic development, wound healing, synaptogenesis, and neoplasia. These proteins mediate the interaction of normal and neoplastic cells with the extracellular matrix and surrounding tissue. In the tumor microenvironment, TSP-1 has been shown to suppress tumor growth by inhibiting angiogenesis and by activating transforming growth factor beta. TSP-1 inhibits angiogenesis through direct effects on endothelial cell migration and survival, and through effects on vascular endothelial cell growth factor bioavailability. In addition, TSP-1 may affect tumor cell function through interaction with cell surface receptors and regulation of extracellular proteases. Whereas the role of TSP-1 in the tumor microenvironment is the best characterized, the other TSPs may have similar functions. (Part of a Multi-author Review).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18193162      PMCID: PMC2752021          DOI: 10.1007/s00018-007-7486-z

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  104 in total

1.  Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.

Authors:  D Albo; D H Berger; J Vogel; G P Tuszynski
Journal:  J Gastrointest Surg       Date:  1999 Jul-Aug       Impact factor: 3.452

2.  Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte attachment through interaction with integrins.

Authors:  Faye Hui Chen; Ashby O Thomas; Jacqueline T Hecht; Mary B Goldring; Jack Lawler
Journal:  J Biol Chem       Date:  2005-07-28       Impact factor: 5.157

3.  Characterization of integrin beta6 and thrombospondin-1 double-null mice.

Authors:  Anna Ludlow; Karen O Yee; Ruth Lipman; R Bronson; P Weinreb; Xiaozhu Huang; D Sheppard; J Lawler
Journal:  J Cell Mol Med       Date:  2005 Apr-Jun       Impact factor: 5.310

Review 4.  Differentiation of tumours of ductal and lobular origin: II. Genomics of invasive ductal and lobular breast carcinomas.

Authors:  Gulisa Turashvili; Jan Bouchal; George Burkadze; Zdenek Kolár
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2005-06       Impact factor: 1.245

5.  Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.

Authors:  Aurélie Fontana; Stéphanie Filleur; Julien Guglielmi; Lucien Frappart; Gabriella Bruno-Bossio; Sandrine Boissier; Florence Cabon; Philippe Clézardin
Journal:  Int J Cancer       Date:  2005-09-20       Impact factor: 7.396

6.  Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.

Authors:  M Streit; P Velasco; L F Brown; M Skobe; L Richard; L Riccardi; J Lawler; M Detmar
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

7.  Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis.

Authors:  S Kanda; T Shono; B Tomasini-Johansson; P Klint; Y Saito
Journal:  Exp Cell Res       Date:  1999-11-01       Impact factor: 3.905

8.  Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers.

Authors:  Barbro Linderholm; Eva Karlsson; Sigrid Klaar; Thomas Lindahl; Anna-Lena Borg; Göran Elmberger; Jonas Bergh
Journal:  Eur J Cancer       Date:  2004-11       Impact factor: 9.162

9.  The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex.

Authors:  Geoffrey D Young; Joanne E Murphy-Ullrich
Journal:  J Biol Chem       Date:  2004-09-01       Impact factor: 5.157

10.  Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins.

Authors:  Sarah M Short; Alexandrine Derrien; Radha P Narsimhan; Jack Lawler; Donald E Ingber; Bruce R Zetter
Journal:  J Cell Biol       Date:  2005-02-14       Impact factor: 10.539

View more
  113 in total

1.  Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.

Authors:  Philip P Fitchev; Susan M Wcislak; Chung Lee; Anders Bergh; Charles B Brendler; Veronica M Stellmach; Susan E Crawford; Constantine D Mavroudis; Mona L Cornwell; Jennifer A Doll
Journal:  Lab Invest       Date:  2010-05-10       Impact factor: 5.662

2.  Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

Authors:  Yibing Ruan; Anna Kovalchuk; Aarthi Jayanthan; Xueqing Lun; Yoji Nagashima; Olga Kovalchuk; James R Wright; Alfredo Pinto; Adam Kirton; Ronald Anderson; Aru Narendran
Journal:  Neuro Oncol       Date:  2014-11-12       Impact factor: 12.300

3.  A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome.

Authors:  Zhi Zeng; Marina Hincapie; Sharon J Pitteri; Samir Hanash; Joost Schalkwijk; Jason M Hogan; Hong Wang; William S Hancock
Journal:  Anal Chem       Date:  2011-05-23       Impact factor: 6.986

4.  Regional control of tumor growth.

Authors:  Alexander Zaslavsky; Catherine Chen; Jenny Grillo; Kwan-Hyuck Baek; Lars Holmgren; Sam S Yoon; Judah Folkman; Sandra Ryeom
Journal:  Mol Cancer Res       Date:  2010-08-24       Impact factor: 5.852

5.  Emerging functions of matricellular proteins.

Authors:  David D Roberts
Journal:  Cell Mol Life Sci       Date:  2011-08-11       Impact factor: 9.261

Review 6.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

7.  CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.

Authors:  Kavya Rakhra; Pavan Bachireddy; Tahera Zabuawala; Robert Zeiser; Liwen Xu; Andrew Kopelman; Alice C Fan; Qiwei Yang; Lior Braunstein; Erika Crosby; Sandra Ryeom; Dean W Felsher
Journal:  Cancer Cell       Date:  2010-10-28       Impact factor: 31.743

8.  Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.

Authors:  Alessandro Prete; Agnes S Lo; Peter M Sadow; Swati S Bhasin; Zeus A Antonello; Danica M Vodopivec; Soumya Ullas; Jennifer N Sims; John Clohessy; Ann M Dvorak; Tracey Sciuto; Manoj Bhasin; Joanne E Murphy-Ullrich; Jack Lawler; S Ananth Karumanchi; Carmelo Nucera
Journal:  Clin Cancer Res       Date:  2018-08-03       Impact factor: 12.531

9.  Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.

Authors:  Li Jia; David J Waxman
Journal:  Cancer Lett       Date:  2012-12-08       Impact factor: 8.679

Review 10.  Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.

Authors:  Y Mirochnik; A Kwiatek; O V Volpert
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.